Interactive Pages | Contact Us
| Home | About Us | Treatments | Clinical Trials | Research | News | Opinions & Features | Helpful Links |
| Citalopram (CelexaŽ) | | Print | |
|
Related Articles
Completed Trials Tetrabenazine (Nitoman®, Xenazine®) Active Trials Planned Trials Related Links What is a Clinical Trial?by Huntington Study Group (HSG) Understanding Clinical Trials by NIH ClinicalTrials.gov List of Clinical Trials by NIH ClinicalTrials.gov List of Clinical Trials by Huntington Project National Institute of Neurological Disorders and Stroke (NINDS) Trial information at NIH ClincalTrials.gov Trial status: Enrolling at University of Iowa. Trial name: CIT-HD FDA phase: Phase II Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Trial design: A randomized, double-blind, placebo-controlled, pilot clinical trial in 20 people with HD between the ages of 18 and 60, to consider the efficacy of citalopram. The trial lasts about 21 weeks and requires eight outpatient visits and two telephone visits. Participants will be offered travel reimbursement and some compensation for participation. Outcome measures: Comparison of executive function before and after treatment. Other assessments include cognitive and functional measures and brain imaging. Location: University of Iowa Contact information: Please contact William H. Adams, study coordinator, by phone at 1-319-353-4411, or by e-mail at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it |
| < Prev | Next > |
|---|